45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
April 2017 in “The journal of sexual medicine” 5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
36 citations
,
July 2022 in “Journal of Medicinal Chemistry” Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
27 citations
,
January 1984 in “Pharmacology & Therapeutics” Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
8 citations
,
December 2020 in “The FASEB Journal” Blocking adenosine A2B receptor may prevent or treat hearing loss.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
8 citations
,
October 2016 in “Journal of Investigative Dermatology” MR antagonists may improve skin health and wound healing, especially in aging.
1 citations
,
March 2022 in “British Journal of Clinical Pharmacology” 5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
April 2023 in “Journal of Investigative Dermatology” A new treatment for hair loss shows promise with fewer side effects.
38 citations
,
October 2005 in “Expert opinion on therapeutic patents” Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
26 citations
,
June 1983 in “Journal of Hypertension” Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
14 citations
,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
November 2022 in “Molecular Pharmaceutics” cp-asiAR may effectively treat androgenetic alopecia by promoting hair growth and reducing androgen receptor activity.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
14 citations
,
January 2020 in “International Journal of Biological Sciences” Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
2 citations
,
November 2017 in “Elsevier eBooks” Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
22 citations
,
September 2002 in “Der Urologe” Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.
4 citations
,
December 2019 in “Minerva Urology and Nephrology” 5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.